Adagrasib is a KRAS G12C inhibitor approved for treating non-small cell lung cancer and colorectal cancer. This page compares Adagrasib with other treatments, including Sotorasib (Lumakras), Docetaxel (Taxotere), and Pembrolizumab (Keytruda). While all target specific pathways, Adagrasib offers a distinct profile across its approved indications.
Adagrasib Alternatives: How It Compares to Other KRAS G12C Inhibitors
Hipa.ai Research · Source: ClinicalTrials.gov / AACT · Last updated: AI-augmented data · 0/5 curated
Source: ClinicalTrials.gov via AACT · Hipa.ai, 2026-05-07Download chart as PNG
The competitive landscape includes long-standing treatments such as Docetaxel (Taxotere, approved 1996) and Pembrolizumab (Keytruda, approved 2014). Adagrasib received approval in 2022, while Divarasib and other agents remain in Phase 3, potentially 1-2 years behind.
Quick comparison table
| Drug | Class | Approved indications | Dosing | Year approved | Lead pivotal endpoint | Annual cost (rough) |
|---|---|---|---|---|---|---|
| Adagrasib (Krazati) | KRAS G12C inhibitor | Non-small cell lung cancer, Colorectal cancer | 600 mg orally twice daily | Pipeline | 43% | $237k |
| Sotorasib (Lumakras) | KRAS G12C inhibitor | Non-small cell lung cancer, Colorectal cancer | 960 mg orally once daily | Pipeline | 36% | $215k |
| Docetaxel (Taxotere) | Microtubule inhibitor | Breast cancer, Non-small cell lung cancer, Prostate cancer, +2 more | 75 mg/m2 intravenously every 3 weeks | Pipeline | — | $3k |
| Pembrolizumab (Keytruda) | PD-1 inhibitor | melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, +3 more | 200 mg every 3 weeks or 400 mg every 6 weeks intravenously | Pipeline | Overall Survival: 0.6Hazard Ratio @ 5 years | $191k |
| Divarasib | KRAS G12C inhibitor | — | 400 mg orally once daily | Pipeline | — | — |
Cost estimates are list-price approximations and do not reflect rebates, formulary tier, or out-of-pocket costs after benefits. The class-typical lead-pivotal endpoint here is Objective Response Rate (ORR); cells render each drug's actual pivotal endpoint, which may differ. The "Year approved" column shows the FDA approval year for KRAS G12C-mutated NSCLC specifically — drugs approved for other indications first appear with their this-indication date, or as Pipeline if not yet approved for this indication. Cross-trial comparisons can mislead — head-to-head Phase-3 data (when present) is below.
Adagrasib vs Sotorasib (Lumakras)
The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT06497556) enrolling 338 participants, primary completion 2027-09.
Primary-endpoint values for NCT06497556 are not yet posted in the AACT results database.
Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.
Adagrasib vs Docetaxel (Taxotere)
No head-to-head Phase-3 trial directly compares Adagrasib with Docetaxel.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Adagrasib vs Pembrolizumab (Keytruda)
The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT04613596) enrolling 806 participants, primary completion 2028-10.
Primary-endpoint values for NCT04613596 are not yet posted in the AACT results database.
Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.
Pipeline alternatives
Investigational IL-17 / IL-17-related drugs currently in active Phase 3 development include Sotorasib from Amgen, which is being evaluated in a lead Phase 3 trial, NCT05920356. Docetaxel, sponsored by AstraZeneca, is also undergoing Phase 3 investigation with its lead trial identified as NCT00076388. Pembrolizumab, from Merck Sharp & Dohme LLC, is being studied in its lead Phase 3 trial, NCT01905657. Additionally, Divarasib by Hoffmann-La Roche is in active Phase 3 development, with its lead trial designated as NCT03178552.
Choosing between Adagrasib and its alternatives
Adagrasib, as a targeted KRAS G12C inhibitor, offers a specific mechanism of action for patients with this mutation. Its direct inhibition of the mutated KRAS protein may be a key consideration for clinicians seeking a highly specific intervention. While specific efficacy data for adagrasib is not provided here, its targeted approach positions it as a direct competitor to other KRAS G12C inhibitors.
Other treatment options present different considerations. Sotorasib (Lumakras), also a KRAS G12C inhibitor, has demonstrated an Objective Response Rate (ORR) of 36% and is dosed at 960 mg orally once daily. For patients requiring a different mechanism, docetaxel (Taxotere), a microtubule inhibitor, is administered intravenously at 75 mg/m2 every 3 weeks. Pembrolizumab (Keytruda), a PD-1 inhibitor, offers an immunotherapy approach, demonstrating an Overall Survival Hazard Ratio of 0.6 at 5 years, with dosing options of 200 mg every 3 weeks or 400 mg every 6 weeks intravenously. These alternatives may be chosen based on factors such as prior treatment history, specific tumor biology (e.g., PD-L1 expression), patient preference for oral versus intravenous administration, or considerations of cost and established safety profiles.
Ultimately, the choice of therapy is a complex medical decision that rests with the treating clinician in consultation with their patient.
Sources and methodology
Trial data was pulled from the ClinicalTrials.gov registry via the AACT relational mirror maintained by the Clinical Trials Transformation Initiative. AACT data freshness: .
Head-to-head trials cited on this page:
- NCT06497556: Adagrasib vs Sotorasib · A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Tr…
- NCT04613596: Adagrasib vs Pembrolizumab · Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combina…
- NCT06497556: Adagrasib vs Divarasib · A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Tr…
Cross-trial comparison limitations:drugs without a direct head-to-head trial are compared using each drug's own pivotal trial. These trials enrolled different patient populations at different time points and used different statistical analysis sets. Cross-trial response-rate differences should not be interpreted as proof that one drug is more effective than another.
Related drug pages on Hipa.ai
Not medical advice. This page summarizes publicly-reported clinical trial data for informational purposes. Treatment decisions belong with a qualified prescribing clinician who knows your medical history. Drug approvals, dosing, and safety profiles change over time — always confirm with the current FDA prescribing information.
adagrasibadagrasib alternativesalternativescomparisonKRAS G12C-mutated NSCLCadagrasib-kras-g12c-nsclcadagrasib vs sotorasibadagrasib vs docetaxeladagrasib vs pembrolizumabadagrasib vs divarasib